In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.32, marking a -3.36% move from the previous day.

It might take a while for this AI company to prove its worth, if it ever does so.

技術進化が著しい現代において、バックエンドエンジニアの採用は企業にとっての大きな挑戦となっています。この課題に応えるべく、Recursion, Inc（共同創業者：田島慎也、Jeffry Alvarado、本社：アメリカカリフォルニア州）は、Recursion転職を立ち上げました。

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best debt-free penny stocks to buy right now. On December 17, ...

Last year's weakness is ultimately an improved entry opportunity for long-term-minded investors.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.73, representing a -4.64% change from its previous ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Recursion Pharmaceuticals, Inc., a biotechnological firm based in Salt Lake City, Utah, disclosed today that Genentech, Inc. has exercised an option for a Neuroscience Phenomap under a collaboration ...

コンピュータサイエンス学習プラットフォーム「Recursion」を提供するRecursion, Inc（本社：カリフォルニア州ロサンゼルス、共同創業者：田島慎也 、Jeffry Alvarado、以下当社）は、2020年9月8日、初級編に引き続き、「コンピュータサイエンス基礎：中級編」を ...